Amphastar Pharmaceuticals

Update in progress

AMPH (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Amphastar Pharmaceuticals, Inc. is a Rancho Cucamonga, California–based biopharmaceutical company that develops, manufactures, and markets generic and proprietary injectable, inhalation, and intranasal products for the United States, China, and France. Its portfolio includes emergency and diagnostic injectables (BAQSIMI, Glucagon kit, Cortrosyn), asthma/allergy products (Primatene MIST, Epinephrine, Albuterol, Ipratropium), anticoagulants, opioids antidotes, and insulin APIs. Founded 1996.

Company score

Sentiment: 0.44; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.01; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.25; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.04; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive